Clarametyx today announced positive topline data from a Phase 1b/2a trial evaluating its novel antibody therapy, CMTX-101, in cystic fibrosis (CF).

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In ...

Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of AGMB-447 in healthy participants -- ...

In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonst ...

Together, we’ve demonstrated how a modern, ISO 20022-ready wires platform can be deployed efficiently and securely, ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Karnataka to develop a 65-acre tree park at Baiyappanahalli at Rs 37.75 crore. Minister M B Patil shares details on phases, ...

The ginormous "Magnificent Seven" stocks have been the stars of the stock market in recent years. In 2025, international ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...

At the Panacea Biotec office, conversations around DengiAll are cloaked with an air of eagerness. With the human trials ...